Q2 2026 saw 1% net sales growth and flat core operating income, driven by strong performance of key brands and new launches, offsetting generic erosion. Full-year guidance was reaffirmed, with robust pipeline progress and multiple pivotal readouts expected in H2.Based on Novartis AG [NOVN] Q2 2026…
Q2 2026 saw 1% net sales growth and flat core operating income, driven by strong performance of key brands and new launches, offsetting generic erosion. Full-year guidance was reaffirmed, with robust pipeline progress and multiple pivotal readouts expected in H2.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.